Science Explorer Interactive view Map
Topic · Genetics

Myeloproliferative Neoplasms: Diagnosis and Treatment

Myeloproliferative Neoplasms: Diagnosis and Treatment is a research topic within Genetics. Science Explorer counts 23k research works in it since 1950. 11.6% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the molecular pathogenesis, diagnosis, treatment, and prognosis of myeloproliferative disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis. It covers topics such as JAK2 and CALR mutations, prognostic scoring systems, ruxolitinib therapy, hematologic response, leukemic transformation, and stem cell transplantation.

  • JAK2 Mutation
  • Myelofibrosis
  • Polycythemia Vera
  • Thrombocythemia
  • CALR Mutation
  • Prognostic Scoring System
  • Ruxolitinib Therapy
  • Hematologic Response
  • Leukemic Transformation
  • Stem Cell Transplantation
Research works
23k
fractional, since 1950
In the world top 10%
2.7k
per year above
Top-10% rate
11.6%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+31%
the tick is no change

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Myeloproliferative Neoplasms: Diagnosis and Treatment research?

By volume, the United States and China publish the most (1.5k and 537 works in 2022–2025).

By volume, 2022–2025

  1. 1 United States 1.5k works
  2. 2 China 537 works
  3. 3 Italy 301 works
  4. 4 Germany 229 works
  5. 5 France 210 works
  6. 6 India 208 works
  7. 7 Japan 192 works
  8. 8 United Kingdom 187 works
  9. 9 Spain 151 works
  10. 10 Brazil 118 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 41.5%China: 14.7%Italy: 8.2%Germany: 6.3%6 others listed: 29.2%42%largest
United States1,516 · 41.5%China537 · 14.7%Italy301 · 8.2%Germany229 · 6.3%6 others listed1,066 · 29.2%

Shares of the rows listed above, not of the whole node.

Which institutions lead Myeloproliferative Neoplasms: Diagnosis and Treatment research?

By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Myeloproliferative Neoplasms: Diagnosis and Treatment research, followed by Icahn School of Medicine at Mount Sinai and Cleveland Clinic.

By volume, 2022–2025

  1. 1 The University of Texas MD Anderson Cancer CenterUnited States 96 works
  2. 2 Icahn School of Medicine at Mount SinaiUnited States 37 works
  3. 3 Cleveland ClinicUnited States 30 works
  4. 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 29 works
  5. 5 Moffitt Cancer CenterUnited States 28 works
  6. 6 Memorial Sloan Kettering Cancer CenterUnited States 23 works
  7. 7 Mayo ClinicUnited States 22 works
  8. 8 Washington University in St. LouisUnited States 20 works
  9. 9 Institute of Hematology & Blood Diseases HospitalChina 20 works
  10. 10 Mayo Clinic in ArizonaUnited States 19 works

Who are the leading researchers in Myeloproliferative Neoplasms: Diagnosis and Treatment?

The most-cited researchers publishing on Myeloproliferative Neoplasms: Diagnosis and Treatment include Benjamin L. Ebert and Hagop M. Kantarjian.

  1. 1 Benjamin L. Ebert United States 6.7k citations
  2. 2 Hagop M. Kantarjian United States 4k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is Myeloproliferative Neoplasms: Diagnosis and Treatment research done?

The largest centres of Myeloproliferative Neoplasms: Diagnosis and Treatment research in 2022–2025 are New York (United States), Houston (United States), Beijing (China) and Paris (France). Among places with at least 20 works in it, it is an unusually large share of all research in Rochester, Tampa and Houston.

Largest cities, 2022–2025

  1. 1 New York United States 130 works
  2. 2 Houston United States 116 works
  3. 3 Beijing China 97 works
  4. 4 Paris France 91 works
  5. 5 London United Kingdom 70 works
  6. 6 Boston United States 70 works
  7. 7 Tokyo Japan 57 works
  8. 8 Rome Italy 52 works
  9. 9 Seoul South Korea 43 works
  10. 10 Cleveland United States 39 works

Where it is the local speciality

  1. RochesterUS · 22.6 works12×
  2. TampaUS · 36.1 works11×
  3. HoustonUS · 116.3 works9.7×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Myeloproliferative Neoplasms: Diagnosis and Treatment than the world average.

See Myeloproliferative Neoplasms: Diagnosis and Treatment on the map

Where is the best place to study Myeloproliferative Neoplasms: Diagnosis and Treatment?

Among universities, judged by research, Icahn School of Medicine at Mount Sinai, Washington University in St. Louis and Juntendo University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 17.83%fractional works in this node (log) →share in the world top 10% →Icahn School of Medicine at Mount Sinai: 37, 14.4%Washington University in St. Louis: 20, 16.3%Juntendo University: 8, 7.4%Harvard University: 17, 28.3%Chinese Academy of Medical Sciences & Peking Union Medical College: 30, 10.3%University of Florence: 18, 20.3%Weill Cornell Medicine: 8, 12.5%Yale University: 14, 20.6%Université Paris Cité: 10, 24.1%University of Milan: 11, 24.1%Harvard UniversityWashington Universit…Icahn School of Medi…Juntendo University
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Icahn School of Medicine at Mount SinaiUnited States 61.314.4%15.9×37 +80.5%
2 Washington University in St. LouisUnited States 49.516.3%6.0×20 +134.6%
3 Juntendo UniversityJapan 48.77.4%11.8×8 +192.7%
4 Harvard UniversityUnited States 47.728.3%2.9×17 +17.9%
5 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 47.010.3%6.4×30 +130.0%
6 University of FlorenceItaly 47.020.3%7.0×18 -20.7%
7 Weill Cornell MedicineUnited States 47.012.5%13.4×8 —
8 Yale UniversityUnited States 46.920.6%2.9×14 +238.4%
9 Université Paris CitéFrance 44.624.1%4.8×10 +7.7%
10 University of MilanItaly 40.724.1%3.6×11 +26.9%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is Myeloproliferative Neoplasms: Diagnosis and Treatment research growing?

Output in 2018–2022 was 31% higher than in 2013–2017, peaking in 2023. The fastest-growing topics are Myeloproliferative Neoplasms: Diagnosis and Treatment.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.